JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trifilieff, A.
Right arrow Articles by Hersperger, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trifilieff, A.
Right arrow Articles by Hersperger, R.

Vol. 301, Issue 1, 241-248, April 2002

Pharmacological Profile of a Novel Phosphodiesterase 4 Inhibitor, 4-(8-Benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic Acid (NVP-ABE171), a 1,7-Naphthyridine Derivative, with Anti-Inflammatory Activities

Alexandre Trifilieff, Daniel Wyss, Christoph Walker, Lazzaro Mazzoni and Rene Hersperger

Novartis Horsham Respiratory Centre, Horsham, United Kingdom (A.T., D.W., C.W.); and Novartis Pharma AG, Basel, Switzerland (L.M., R.H.)

We investigated the pharmacology of a new class of phosphodiesterase 4 (PDE4) inhibitor, 6,8-disubstituted 1,7-naphthyridines, by using 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171) as a representative compound and compared its potency with the most advanced PDE4 inhibitor, undergoing clinical trials, Ariflo [cis-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl-r-1-cyclohexanecarboxylic acid)]. NVP-ABE171 inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D with respective IC50 values of 602, 34, 1230, and 1.5 nM. Ariflo was about 40 times less potent. In human cells, NVP-ABE171 inhibited the eosinophil and neutrophil oxidative burst, the release of cytokines by T cells, and the tumor necrosis factor-alpha release from monocytes, in the nanomolar range. Ariflo presented a similar inhibition profile but was 7 to 50 times less potent. In BALB/c mice challenged with lipopolysaccharide, NVP-ABE171 inhibited the airway neutrophil influx and activation with an ED50 in the range of 3 mg/kg. Ariflo was inactive up to a dose of 10 mg/kg. In ovalbumin sensitized Brown Norway rats, NVP-ABE171 inhibited the lipopolysaccharide-induced airway neutrophil influx and activation (ED50 of 0.2 mg/kg) and the ovalbumin-induced airway eosinophil influx and activation (ED50 of 0.1 mg/kg). Ariflo was about 100 times less potent in both models. In the ovalbumin model, NVP-ABE171 had a duration of action of more than 24 h. NVP-ABE171 is a novel PDE4 inhibitor that shows activity both in vitro on human inflammatory cells and in vivo in animal models of lung inflammation. This compound class may have potential for the treatment of airway inflammatory conditions such as asthma and chronic obstructive pulmonary diseases.

0022-3565/02/3011-0241$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas
Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 468 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
G. N. Dietsch, C. R. Dipalma, R. J. Eyre, T. Q. Pham, K. M. Poole, N. B. Pefaur, W. D. Welch, E. Trueblood, W. D. Kerns, and S. T. Kanaly
Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity
Toxicol Pathol, January 1, 2006; 34(1): 39 - 51.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Ariga, B. Neitzert, S. Nakae, G. Mottin, C. Bertrand, M. P. Pruniaux, S.-L. C. Jin, and M. Conti
Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation
J. Immunol., December 15, 2004; 173(12): 7531 - 7538.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
S. Oger, C. Mehats, M. S. Barnette, F. Ferre, D. Cabrol, and M.-J. Leroy
Anti-Inflammatory and Utero-Relaxant Effects in Human Myometrium of New Generation Phosphodiesterase 4 Inhibitors
Biol Reprod, February 1, 2004; 70(2): 458 - 464.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
I. Kurucz, S. Toth, K. Nemeth, K. Torok, V. Csillik-Perczel, A. Pataki, C. Salamon, Z. Nagy, J. I. Szekely, K. Horvath, et al.
Potency and Specificity of the Pharmacological Action of a New, Antiasthmatic, Topically Administered Soft Steroid, Etiprednol Dicloacetate (BNP-166)
J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 83 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. P. Singh, E. G. Barrett, R. Kalra, S. Razani-Boroujerdi, R. J. Langley, V. Kurup, Y. Tesfaigzi, and M. L. Sopori
Prenatal Cigarette Smoke Decreases Lung cAMP and Increases Airway Hyperresponsiveness
Am. J. Respir. Crit. Care Med., August 1, 2003; 168(3): 342 - 347.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.